Literature DB >> 7784089

Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV.

M Zörnig1, A Grzeschiczek, M B Kowalski, K U Hartmann, T Möröy.   

Abstract

The Fas/Apo-1 receptor is an integral membrane protein that transduces apoptotic signals upon binding to its natural ligand or to specific antibodies. Loss of Fas/Apo-1 receptor leads in (lpr,lpr) mice to a nonmalignant accumulation of abnormal T-cells very probably due to the lack of induction of apoptosis in peripheral T-cells. It has been reported that soluble forms of Fas/Apo-1 receptor that may interfere with apoptotic signaling occur in patients suffering from various forms of lymphoid neoplasms. Therefore, we wished to investigate whether the loss of proper homeostatic regulation through Fas/Apo-1 receptor mediated apoptosis could influence the process of lymphomagenesis. To this end, we performed two experiments (i) we infected (lpr,lpr) animals with Moloney Murine Leukemia Virus (MoMuLV) that causes T-cell lymphoma in mice and (ii) we crossed (lpr,lpr) animals with E mu L-myc transgenic mice that are prone to develop T- and B-cell lymphoma due to deregulated expression of the L-myc transgene by the immunoglobulin enhancer E mu. We find that infection with MoMuLV did not accelerate the formation of lymphoid neoplasms in (lpr,lpr) mice when compared to infected normal animals. However, E mu L-myc/(lpr,lpr) animals that constitutively express the L-myc transgene in the lymphoid lineage clearly show accelerated formation of T- and B-cell lymphoma when compared to normal E mu L-myc transgenics. These data demonstrate that in cooperation with particular oncogenes impairment of Fas/Apo-1 receptor function can indeed affect and modulate the process of tumor formation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7784089

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

Review 1.  A portrait of the Bcl-2 protein family: life, death, and the whole picture.

Authors:  M Pellegrini; A Strasser
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

2.  Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.

Authors:  Nancy Gordon; Nadezhda V Koshkina; Shu-Fang Jia; Chand Khanna; Arnulfo Mendoza; Laura L Worth; Eugenie S Kleinerman
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

Review 3.  The Fas counterattack: a molecular mechanism of tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

4.  The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms.

Authors:  Kirsten Kabsch; Angel Alonso
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 5.  Exposure of phosphatidylserine on the cell surface.

Authors:  S Nagata; J Suzuki; K Segawa; T Fujii
Journal:  Cell Death Differ       Date:  2016-02-19       Impact factor: 15.828

6.  Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas.

Authors:  J Peli; M Schröter; C Rudaz; M Hahne; C Meyer; E Reichmann; J Tschopp
Journal:  EMBO J       Date:  1999-04-01       Impact factor: 11.598

7.  Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma.

Authors:  M S Shin; W S Park; S Y Kim; H S Kim; S J Kang; K Y Song; J Y Park; S M Dong; J H Pi; R R Oh; J Y Lee; N J Yoo; S H Lee
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

8.  Essential role for hematopoietic Fas ligand (FasL) in the suppression of melanoma lung metastasis revealed in bone marrow chimeric mice.

Authors:  Christopher L Hall; Mike Yao; Laurie L Hill; Laurie B Owen-Schaub
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

9.  TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis.

Authors:  Niklas Finnberg; Andres J P Klein-Szanto; Wafik S El-Deiry
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

Review 10.  T cell-tumor cell: a fatal interaction?

Authors:  D B Chappell; N P Restifo
Journal:  Cancer Immunol Immunother       Date:  1998-10       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.